title: Effects of telenzepine and L-364,718 on canine pancreatic secretion before and after vagotomy.
abstract: In six conscious dogs we compared the action of the M1-receptor antagonist telenzepine (20.25-81.0 nmol.kg-1.h-1), the cholecystokinin (CCK) antagonist L-364,718 (0.025-0.1 mg.kg-1.h-1), and combinations of both on the pancreatic secretory response to intraduodenal tryptophan, given against a secretin background before and after truncal vagotomy. Before vagotomy, the higher doses of telenzepine and of L-364,718 significantly (P < 0.05) decreased the protein response to tryptophan by up to 97%. After vagotomy, all doses of L-364,718 abolished the protein response, whereas telenzepine had no further effect. Before and after vagotomy, all combinations abolished the protein response. The plasma CCK-like immunoreactivity basally, during secretin, and in response to tryptophan was not altered by vagotomy, telenzepine, and/or L-364,718. These findings indicate that in dogs 1) potentiation exists between M1 receptors and CCK for stimulation of the pancreatic enzyme response to intraduodenal tryptophan, 2) the cholinergic fibers of the enteropancreatic reflex activated by tryptophan run within the vagus nerves and end at least in part on M1 receptors, 3) CCK acts in part independently of the vagal nerves, and 4) the CCK release by intestinal tryptophan is not influenced by vagotomy, telenzepine, and/or L-364,718.
authors.affiliation: Department of Medicine IV (Gastroenterology), University Hospital of Heidelberg at Mannheim, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Niebergall-Roth
authors.forename: S
authors.initials: S
authors.lastname: Teyssen
authors.forename: D
authors.initials: D
authors.lastname: Wetzel
authors.forename: M
authors.initials: M
authors.lastname: Hartel
authors.forename: C
authors.initials: C
authors.lastname: Beglinger
authors.forename: R L
authors.initials: RL
authors.lastname: Riepl
authors.forename: M V
authors.initials: MV
authors.lastname: Singer
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002766:Cholecystokinin / Q000097:blood / Q000378:metabolism*; D003847:Deoxyglucose / Q000494:pharmacology; D020109:Devazepide; D004285:Dogs; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology*; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D010189:Pancreatic Juice / Q000187:drug effects / Q000378:metabolism*; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D012633:Secretin / Q000494:pharmacology; D012844:Sincalide / Q000037:antagonists & inhibitors; D014364:Tryptophan / Q000494:pharmacology; D015167:Vagotomy, Truncal
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D010276:Parasympatholytics; C046338:telenzepine; D012633:Secretin; D010890:Pirenzepine; D014364:Tryptophan; D002766:Cholecystokinin; D003847:Deoxyglucose; D020109:Devazepide; D012844:Sincalide